Monitor next quarterly Form 10-Q for any changes in cash runway or clinical trial progress, as insider sales remain within routine ranges and do not signal material concern. No immediate catalyst is evident from the trading pattern.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $28.78entry
- T+1 · 7mo ago −0.69%α −1.91% · $28.58
- T+5 · 7mo ago −5.18%α −6.16% · $27.29
- T+20 · 6mo ago +14.45%α +8.64% · $32.94
- T+60 · 4mo ago +21.86%α +14.81% · $35.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite executives at Pharvaris sold shares in the past week, including CEO Modig Berndt and CMO Lu Peng, generating a combined $276K from open-market sales. The transactions follow routine option exercises, with cashless exercises and tax-related dispositions also reported.
Key Financial Metrics
Key Facts
- CEO Modig Berndt sold 2,300 shares at $28.60, generating $66,780 in proceeds.
- CMO Lu Peng sold 7,001 shares at $30.0531, generating $210,401.75 in proceeds.
- Total open-market sales in the cluster amount to $276,181.75.
- Additional derivative exercises and tax-withholding transactions (codes A, M, F) occurred but are non-cash events.
- Total insider sales over the last 30 days now amount to $921K, still under 0.1% of the $1.8B market cap.
Financial Impact
$276K in total open-market sales over 7 days, representing 0.015% of market cap
Risk Factors
- Perception risk if additional executives increase selling in coming weeks.
- Lack of insider buying may signal muted near-term conviction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1777044469272 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers